List view / Grid view
Alirocumab monotherapy reduced “bad” cholesterol three times more than ezetimibe...
16 October 2013 | By Sanofi
Alirocumab monotherapy reduced “bad” cholesterol three times more than ezetimibe...
Comprehensive SARIL-RA development program to include 2,600 patients in four…
15 May 2013 | By Sanofi
Comprehensive SARIL-RA development program to include 2,600 patients in four Phase 3 and one open-label extension trials...
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc.…
2 March 2013 | By Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting…
First and only agent to statistically significantly improve survival in…
5 February 2013 | By Sanofi
First and only agent to statistically significantly improve survival in combination with FOLFIRI chemotherapy after an oxaliplatin regimen...
“We are pleased that CHMP has supported our ZALTRAP application..."
16 November 2012 | By Sanofi
“We are pleased that CHMP has supported our ZALTRAP application..."
ODYSSEY will comprise over 10 clinical trials...
20 July 2012 | By Sanofi
ODYSSEY will comprise over 10 clinical trials...
Data from two Phase 2 trials announced...
26 March 2012 | By Sanofi
Data from two Phase 2 trials announced...
Sanofi and Regeneron Pharmaceuticals, Inc. announced results from Phase 2b…
12 July 2011 | By Sanofi
Sanofi and Regeneron Pharmaceuticals, Inc. announced results from Phase 2b trials...
Data will be presented at the ESMO World Congress on…
6 June 2011 | By Sanofi
Data will be presented at the ESMO World Congress on Gastrointestinal Cancer...
